[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy Academic Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Fluorodeoxyglucose F18
  • Neoplasms
  • Positron-Emission Tomography
  • Protein Kinases
  • Proto-Oncogene Proteins c-akt
  • Radiopharmaceuticals
  • Sirolimus

abstract

  • FDG-PET is not predictive of proliferative response to mTOR inhibitor therapy in both clinical and preclinical studies. Our findings suggest that mTOR inhibitors suppress the formation of mTORC2 complex, resulting in the inhibition of Akt and glycolysis independent of proliferation in a subset of tumors. Changes in FDG-PET may be a pharmacodynamic marker for Akt activation during mTOR inhibitor therapy. FDG-PET may be used to identify patients with persistent Akt activation following mTOR inhibitor therapy.

publication date

  • June 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2689846

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.18.8383

PubMed ID

  • 19380450

Additional Document Info

start page

  • 2697

end page

  • 704

volume

  • 27

number

  • 16